Form 4: Ligand Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Summary

• On February 27, 2024, Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, acquired 7,208 Restricted Stock Units (RSUs) and 29,272 stock options.
• The RSUs vest in three substantially equal annual installments on February 15, 2025, February 15, 2026, and February 15, 2027, contingent upon continued service.
• The stock options vest as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter.
• Following the reported transactions, Reardon directly owns 22,205 shares of common stock and 29,272 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The vesting schedule suggests a long-term commitment from the executive.

Positives

• The acquisition of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize continued service and contribution to the company's success.

Industry Context

Stock options and RSU grants are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in the pharmaceutical industry to align management's interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• The grant of stock options and RSUs to the Chief Legal Officer could positively impact shareholder value by incentivizing the executive to contribute to the company's long-term success.

Key Dates